<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04349566</url>
  </required_header>
  <id_info>
    <org_study_id>FAST TROPONIN</org_study_id>
    <nct_id>NCT04349566</nct_id>
  </id_info>
  <brief_title>Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases</brief_title>
  <official_title>Fast Troponin as a Biomarker to Assess Exercise-induced Muscle Damage in Muscle Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mads Peter Godtfeldt Stemmerik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edgewise Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to explore the biomarker Fast Troponins response to exercise in
      patients with Becker muscular dystrophy, Limb-girdle muscular dystrophy and McArdle disease
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in biomarkers</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in Fast and slow Troponin I after muscle damage</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Becker Muscular Dystrophy</condition>
  <condition>McArdle Disease</condition>
  <condition>Limb-Girdle Muscular Dystrophy Type 2</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with McArdle disease and patients with two sub-typesof Limb-girdle and Becker
        muscular dystrophies will be included as well as healthy controls.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The ability to cycle

          -  No concurrent medical condition that could interfere with interpretation of the
             results

          -  Molecular diagnosis of the specific condition in specified patient groups or healthy
             control

          -  No active muscle injury on the test day (caused by recent exercise, seizures, trauma,
             etc.)

        Exclusion Criteria:

          -  Competing conditions at risk of compromising the results of the study

          -  Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous
             exercise

          -  Veins that are too difficult to puncture for blood sampling, evaluated by the
             investigator

          -  Severe muscle weakness, that prevents the subject completing the exercise test,
             evaluated by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neuromuscular Research Unit, 3342</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Mads Peter Godtfeldt Stemmerik</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Dystrophies, Limb-Girdle</mesh_term>
    <mesh_term>Glycogen Storage Disease Type V</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

